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Summary Neuron specific enolase (NSE) is widely used as a neuro-endoctrine marker. However the presence of NSE in many non-neuroendocrine tissues has raised questions on the specificity of NSE. We have investigated NSE immunoreactivity (NSA-ag), y-enolase activity and total enolase activity in small cell lung
cancer (SCLC) cell lines. During well-controlled exponential growth comparison of NSE-ag content and
y-enolase activity with the doubling-time (Td) and NSE-ag content with y-enolase and total enolase activity led
to a clear distinction of two types of cell line: variant cell lines plus part of the classic cell lines (type I) and the remaining classic cell lines (type II). The distinction was based upon both an abrupt 6-fold increase of
y-enolase activity and an 18-fold increase of NSE-ag, which for the larger part was enzymatically inactive.
Within each group the increase of NSE-ag content was significantly correlated with the increase of y-enolase
activity and both NSE-ag content and y-enolase activity increased linearly with Td. It is concluded that y-enolase seems to be associated with the regulation of growth rate and that a compound with the y-enolase antigen but without enzyme activity can distinguish two different classes of SCLC cell lines. Furthermore the
demonstration that NSE-ag can represent the active enzyme as well as an enzymatically inactive compound
may explain why a controversy about neuron- or non-specificity of NSE exists.
Since the beginning of the eighties numerous continuously
growing cell-lines from Small Cell Lung Cancer (SCLC)
biopsies have been established. Investigators at the National
Cancer Institute (Bethesda, USA) were the first to distinguish
two types of cell-lines i.e. variant and classic cell-lines, char-
acterised by the absence or presence respectively of the
enzyme L-dopadecarboxylase. In comparison with classic cell
lines variant cell lines were shown to have a higher growth
rate, a higher cloning efficiency, a larger cell volume, a lower
content of Neuron-Specific Enolase (NSE), amplification of
c-myc, absence of gastrin releasing peptide (GRP) and
neurotensin, and a decreased sensitivity to radiotherapy and
chemotherapy (Bepler et al., 1987; Carney et al., 1985; Gaz-
dar et al., 1985; Bepler et al., 1989a; Broers et al., 1985;
Moody et al., 1985; Broers et al., 1988). Recently Bepler et
al. (1989b) added a third class, so-called transitional cells,
based on the presence of p64 c-myc in some of the classic cell
lines. The addition of a third class of cell lines, is substan-
tiated by intermediate levels of neuroendocrine markers,
growth rate and cloning efficiency.
NSE is widely used as a neuroendocrine marker. NSE-
immuno reactivity is not only seen in neurons, but also in
neuroendocrine cells present in endocrine glands and in the
diffuse neuroendocrine systems of the lung, intestine, thymus
and skin. NSE has been demonstrated in tumours, thought
to arise from the neuroendocrine cell system, such as SCLC,
neuroblastoma, carcinoid, pancreatic islet cell tumours and
medullary thyroid carcinoma (Schmechel et al., 1978; Tapia
et al., 1981; Wick et al., 1983). NSE is also present in
erythrocytes, lymphocytes and platelets (Marangos et al.,
1980b; Hullin et al., 1980) and in malignant lymphomas,
testicular cancer, hypernephroma and non-small cell lung
cancer (Takashi et al., 1989; Ariyoshi et al., 1983; Kuzmits et
al., 1987; Pinto et al., 1989; Oka et al., 1989; Niehans et al.
1988). Such observations question the correlation between
NSE and the neuroendocrine cell system (Schmechel, 1985).
We have investigated the relationship between NSE-
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immunoreactivity and enolase-enzyme activity in SCLC-cell
lines. It was found that immunoreactive NSE can represent
the active enzyme y-enolase as well as an enzymatically in-
active compound. The active enzyme was linearly correlated
with the growth rate and the presence of the inactive com-
pound distinguished two different classes of SCLC-cell lines.
Materials and methods
SCLC-cell lines
The SCLC-cell lines were generously provided by the Dept.
of Clinical Immunology, University of Groningen, The
Netherlands. The following cell lines were used GLC-1,
GLC-2, GLC-3, GLC-4, GLC-1-13, GLC-8, GLC-l1, GLC-
14, GLC-16, GLC-19. GLC-28 and GLC-34. The first four
cell lines were cultured in RPMI 1640 (Gibco) supplemented
with 10% heat-inactivated foetal calf serum (Gibco), the
remaining cell lines in serum free RPMI 1640 supplemented
with hydrocortisone, insulin, transferrin, 17-p-estradiol,
sodium selenite, bombesin and vasopressin as previously des-
cribed (De Leij et al., 1985).
Samplepreparation
A cell pellet, containing 1-3 x 106 cells, was obtained by
centrifugation for 10min at 250g. In order to remove dead
cells and cell debris the pellet was washed once with PBS and
treated with 1 ml of 0.05% Trypsin-0.02% EDTA (Flow
Laboratories) for 3 min at 37°C. To inactivate trypsin culture
medium supplemented with 10% foetal calf serum was
added. Then DNAse (Sigma DN-25) was added to a final
concentration of 0.1%. After mixing an aliquot of the single
cell suspension was used for cell counting in a
haemocytometer.
The remaining cells were centrifuged at 800g and the pellet
was frozen at - 70°C. After thawing the cell pellet was
suspended in 0.5 ml of 50 mM Tris-HCI buffer pH 8.0 con-
taining 100 mM KCI, 10mM MgCI2, 2 mM dithiotreitol and
100 mM sucrose. After centrifugation for 10min at 800g the
supernatant was used for measuring neuron specific enolase
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immunoreactivity, enolase enzyme activity, enolase isoenzyme
composition and protein content.
Neuron specific enolase immunoreactivity
NSE-immunoreactivity (NSE-ag) was determined with the
Pharmacia NSE-RIA, as previously described (Cooper et al.,
1985).
Enolase enzyme activity
Enolase (2-phospho-D-glycerate hydrolase: EC4.2.1.11)
activity was measured in 100 mM Tris/HCI buffer pH 8.0,
containing 100 mM MgCl2, 100 mM KCI, 0.5 mM EDTA,
1.5 mM ADP (Boehringer), 0.2 mM NADH (Sigma),
0.5 U ml-' pyruvate kinase (Boehinger) and 1.0 U ml-' lac-
tate dehydrogenase (Boehringer). The reaction mixture was
preincubated for 10 min at 30°C. The reaction was started
with the substrate glycero-2-phosphate 1 mM (Boehringer)
and assayed kinetically in a Philips PU 8720 spec-
tophotometer at 340 nm and 30°C (Oskam et al., 1985). The
supernatant was chosen so as to contain an enolase enzyme
activity between 50 and 500 U 1' within these values a linear
correlation existed between enolase enzyme activity and pro-
tein content of the different cell lines.
Enolase isoenzymes
Enolase isoenzymes were separated on cellulose acetate gel
(Cellogel) in 20 mM sodium-phosphate buffer pH 7.0 and
enolase activity as determined as described previously (Osk-
ram et al., 1985).
L-dopa decarboxylase
L-dopa decarboxylase (aromatic L-amino acid decarboxylase;
ALAAD) was measured as described previously (Boomsma
et al., 1986) and expressed as mU 10-6 cells. For measuring
ALAAD activity a frozen cell pellet, containing a known
number of cells, was dissolved and further diluted when
necessary in bidistilled water containing 40 gI` of bovine
serum albumin and 10gl-l of glutathione.
Purification ofNSE andproduction ofantiserum
Human NSE was purified from postmortem human brain
cortex and the antiserum was produced in rabbits (Haglid et
al., 1973). This antiserum was extensively absorbed with
human non-neuronal enolase until the resulting rabbit anti-
NSE did not show any crossreactivity with a-enolase in an
ELISA (Aurell et al., 1989).
differences between the means of two groups was tested by
the Student's t-test. When a P-value was less than 0.05 the
difference was regarded significant.
Doubling time (Td) and NSE-immunoreactivity (NSE-ag)
During strictly controlled exponential growth the doubling-
time, NSE-ag, enolase and ALAAD-enzyme activity were
measured in 23 different passages of 11 different cell lines
(GLC-1, 2, 4, 1-13, 8, 11, 14, 16, 19, 28 and 34). The first
three cell lines (GLC-1, 2 and 4) did not contain ALAAD
activity and were therefore called variant, the remaining cell
lines were classified as classic. As shown in Figure 1 the
NSE-ag/Td ratio distinguished two groups ofcell lines: at the
left GLC-1, 2, 4, 1-13, 8, 11, 16, 19 and earlier passages of
GLC 14 and 28; at the right GLC-34 and later passages of
GLC-14 and 28. Each group showed a highly significant
correlation between NSE-ag content and Td. (Correlation
coefficients were 0.95 and 0.99 of the left and right group
respectively, the P-values<0.0001 for both). The mean NSE-
ag level was significantly different between both groups
(606 ± 250 vs 1852 ± 293 ngmg-' protein, P<0.0001). More-
over the NSE-ag levels of both groups did not show an
overlap. Although the mean Td of the left group was signifi-
cantly different from the Td of the right group (36.9 ± 10.4 h
53 ± 17 h respectively, P = 0.01), there was an evident over-
lap of Td's between both groups. The mean ALAAD-activity
of only the classic cell lines in both groups was similar
(0.805 ± 0.574 and 0.818 ± 0.606 mU 10-6 cells, P = 0.9) and
the mean enolase-activity of the left and the right group was
0.856 ± 0.213 and 0.624 ± 0.117 U mg-' protein respectively
(P = 0.02). The cell lines, belonging to the group at the left in
Figure 1, were called type I and the cell lines on the right
type II.
NSE-immunoreactivity (NSE-ag), total enolase- andy-enolase
enzyme activity
As shown in Figure 2 the ratio between NSE-ag content and
total enolase activity, measured in the same cell lines of the
paragraph above, also distinguished the same two types of
cell lines with the exception of GLC 1-13 and 16 (open
squares). The mean ratio for type I cell lines was
635 ± 144 ng U ' and for the right group 2994 ± 350 ng U-'
(P<0.0001). These data indicated the existence of an abrupt
increase of NSE-ag without enzyme activity between the two
types ofcell lines. The ratios for the two exceptional cell lines
were 1193 and 1294 respectively. Both cell lines had NSE-ag
contents in earlier passages consistent with type II cell lines.
Six and nine passages later the Td had decreased from 56 to
35 h and from 60 to 39 h respectively at which time the ratio
Immunoblotting with anti-NSE
Samples of the various SCLC-cell lines were sonicated (Bran-
son, Sonifier, cell disruptor B15) in 1% SDS at 90°C until a
clear solution was obtained, usually no longer than 60 sec.
(Wang et al., 1990). Samples of sonicated SCLC-cell lines
were run in SDS gel electrophoresis, using a 5-10% linear
polyacrylamide slab gel. The proteins were transferred to a
0.45 ItM nitrocellulose membrance according to Towbin et al.
(1979) except that 0.1% SDS was added to the transfer
buffer. The electrophoretic blots were detected using rabbit
anti-NSE serum (absorbed xix) (diluted 1:500 in TRIS-
buffered saline) as the first antibody and peroxidase-
conjugated goat anti-rabbit IgG (diluted 1:200) as the second
antibody Diaminobenzidine (0.5 mgml-' in TBS) and H202
(0.03%) were used as the enzyme substrate for the colour
reaction.
Statistical methods
The date are presented as the mean ± the standard deviation
of the mean. Correlation coefficients were estimated by using
a simple linear regression analysis. The significance of the
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Figure 1 Correlation between intracellular NSE-ag content and
Td during well-controlled exponential growth. Correlation co-
efficients are 0.95 and 0.99 respectively and P-valves <0.0001. 0
( = variant) plus * ( = classic) are called type I, A ( = classic) is
called type II.
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Figure 2 Correlation between intracellular NSE-ag and enolase
enzyme activity during well-controlled exponential growth. a
( = variant) plus * ( = classic) are called type I, A ( = classic) is
called type II, 0 = intermediate cell lines between type I and II.
between enolase-activity and NSE-ag content completely
fitted in the type I cell lines. This observation suggested that
the intermediate values, shown in Figure 2, were due to a
mixture of type I and II cell lines on their way to type I cell
lines. In order to investigate this hypothesis a type II sample
of GLC-16 with a Td of 60 h and a type I sample of GLC-16
with a Td of 28 h were cultured as a 1:1 mixture. At the start
of the mixed culture the enolase/NSE-ag ratio showed an
intermediate value. At each passage the Td and enolase/NSE-
ag ratio decreased until after 5 passages a Td of 30 h and an
enolase/NSE-ag ratio of 700 was reached and remained con-
stant thereafter (data not shown). These data support the
existence of an abrupt instead ofa gradual change ofNSE-ag
without enzyme activity.
In a separate experiment with 24 different passages of
GLC-1, 8, 11, 14, 19, 28 and 34 the percentage of
enzymatically active oaa, cry, 'y chains was measured. The
percentage of enzymatically active y-chains was calculated by
adding halfof the percentage ofay-isoenzymes and two times
the percentage of yy-isoenzymes. NSE-ag was determined in
only 13 of these cell lines. The ratio between y-enolase
activity and NSE-ag level again distinguished two types of
cell lines, which were further characterised by a significant
difference of the mean enolase activity, mean NSE-ag content
and mean Td and an abrupt increase of NSe-ag without
enzyme activity between both types (data not shown). In
addition the mean y-enolase activity of the two groups was
33.5 ± 29 mU mg-' protein and 150 ± 45 mU mg' protein
(P<0.0001) respectively and the mean percentage of
enzymatically active 'y-chains 4.2 ± 2.3% and 25.9 ± 3.6%
(P<0.0001) respectively. As shown in Figure 3 a significant
correlation was found between the log y-enolase activity and
log NSE-ag content in both types (y = 1.39 x - 1.11,
r=0.94, P=0.001 for type I; y= 1.28 x-1.83, r=0.97,
P= 0.005 for type II). Interestingly the slope of both regres-
sion lines was almost identical. These data indicate that the
logarithmic increase of y-enolase activity is significantly cor-
related with the logarithmic increase ofNSE-ag content in an
almost identical way in both types of cell lines but at a
different NSE-ag level. The NSE-ag level shows an abrupt
increase without enzyme activity between both types.
The percentage of enzymatically active 'y-chains in type I
cell lines was significantly correlated with the y-enolase
activity. However no such correlation was observed in type II
cell lines (Figure 4).
Immunoblotting
An immunoblotting assay with polyclonal rabbit antibodies
against human --enolase was performed on extracts of a
variant (GLC-2), a transitional (GLC-8) and a classic (GLC-
34) cell line. Purified human yy-enolase and human brain
cortex grey matter were used as references. All cell lines
Discussion
The relevance of the distinction between classic, transitional
and variant cells in vitro has not been demonstrated in vivo.
This is mainly due to the heterogeneity of the tumour and
difficulty to obtain representative and sufficient tumour
material from patients. Therefore our attention focused on
tumour markers as a possible source of information about
the composition of SCLC-tumours in vivo. Neuron-specific
enolase (NSE) is one of the most widely used tumour
markers in SCLC. It has been shown to be a clinically
reliable tool to monitor the course of the disease (Cooper et
al., 1985; Splinter et al., 1987a; Splinter et al., 1989), the
doubling-time of NSE at relapse was highly significantly
correlated with survival from time of relapse (Splinter et al.,
1987b) and pretreatment-values were shown to have prognos-
tic value by some (J0rgenson et al., 1988), but not by others
(Van der Gaast et al., 1991). Moreover NSE is a good
marker for neuronal differentiation and maturation
(Schmechel et al., 1980). However the presence of NSE in
many non-neuronal and non-neuroendocrine tissues together
with a lack of understanding how a relatively unimportant
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glycolytic enzyme might play such a distinct role in
differentiation raised the question whether NSE was not
neuronspecific but nonspecific (Schmechel, 1985). Therefore
we started to investigate the relationship between NSE and
biological behaviour in SCLC-cell lines. Two types of cell
lines could be distinguished by significant differences of NSE-
ag content, total enolase- and y-enolase enzyme activity, Td
and an abrupt appearance or increase of NSE-ag without
enzyme activity, which was reflected in significantly different
NSE-ag/enolase ratios and NSE-ag/y-enolase ratios. In both
types the NSE-ag content and y-enolase activity (data not
shown) were linearly correlated with the Td, albeit at two
different levels. It is therefore concluded that y-enolase
activity seems to be associated with the regulation of growth
rate. In addition in type II cell lines, but not in type I cell
lines, a dissociation was observed between the percentage of
enzymatically active y-chains and y-enolase activity. This may
indicate that in type II cell lines either the production of
enzymatically active y-chains is dissociated from the produc-
tion of a-chains or active y-chains are inactivated by a
mechanism, which acts independent of the regulation of pro-
duction. Recently it was shown that V-src could induce
phosphorylation of glycolytic enzymes, such as enolase and
especially -y-enolase (Cooper et al., 1983). Phosphorylation of
y-enolase led to partly inactivation of the enzyme, accom-
panied by an increase of the total amount of the enzyme
(Eigenbrodt et al., 1983). Moreover c-src expression in
neuroblastoma- and SCLC-cell lines correlated with neuroen-
docrine differentiation (Mellstrom et al., 1987) and c-src is
connected to neurogenesis and neuronal differentiation
(Brickel et al., 1991), as is the switch from a to y-enolase
(Schmechel et al., 1980). In this connection it is very interes-
ting that Wevers et al. (1988) found in cerebrospinal fluid but
not in serum from healthy individuals that 50% of NSE-ag
had no enzyme activity. These data suggest that NSE-ag
without enzyme activity may arise from inactivation of y-
chains and may be correlated with neuronal or neuroendo-
crine differentiation. However, it is also possible that inac-
tivation of y-enolase by phosphorylation merely reflects pro-
tein kinase activity, leading to different changes in different
cell types. With polyclonal rabbit antibodies against y-
enolase we could not demonstrate the presence of a com-
pound which migrated differently from y-enolase. Whatever
the explanation, characterisation of NSE-ag without enzyme
activity, investigation of the regulation of its production and
of the production of active 'y-enolase may produce more
information about the growth rate and differentiation of
SCLC-cell lines.
The data presented in this paper support the distinction of
two new classes of SCLC-cell lines, type I and II, with
different biological characteristics. Possibly the classic cell
lines, belonging to type I, are similar to the transitional cell
lines, characterised by the presence of p64 c-myc (Bepler et
al., 1989b). Whether such a distinction in vitro has any
relevance in vivo should be and possibly can be investigated
by measuring the ratio between NSE-ag and y-enolase
activity in serum samples from patients with SCLC. A com-
parison ofenzyme activity and immunoreactivity by Sorensen
et al. (1988) in serum samples from five SCLC-patients
showed that at least in some samples the amount of NSE-ag
and y-enolase activity were significantly different.
Finally, the demonstration that 'neuron-specific enolase'
measured with an antibody, can be the enzyme NSE or an
enzymatically inactive compound emphasises that further
investigations about neuron-specificity of NSE needed. It
may be that NSE immunoreactivity in neuroendocrine cells is
different from the one in non-neuroendocrine cells.
We are very grateful for the critical comments and suggestions from
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